Lipedema
Conditions
Brief summary
Women aged 18-75 years with a clinical diagnosis of lipedema and an obese control group will be included in the study. Sociodemographic and clinical data (age, height, weight, medications, etc.) of the participants will be recorded. For laboratory evaluation, fasting blood test results obtained within the last three months (including fasting glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides) will be used. Based on these parameters, metabolic and atherogenic risk indicators such as the Triglyceride-Glucose Index (TyG), TyG-BMI, Atherogenic Index of Plasma (AIP), Atherogenic Coefficient (AC), Castelli Risk Index I (CRI-I), and Castelli Risk Index II (CRI-II) will be calculated. No additional biochemical tests will be collected from participants; analyses will be performed using existing laboratory results.
Interventions
OTHERNo intervention
No intervention
Sponsors
Istanbul Physical Medicine Rehabilitation Training and Research Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Clinically diagnosed with lipedema * Obese control group with BMI ≥30 kg/m² who do not meet lipedema criteria * Aged between 18 and 75 years * Availability of fasting lipid profile and fasting glucose tests within the past 3 months * Provided voluntary informed consent
Exclusion criteria
* Use of medications that routinely affect lipid or glucose metabolism: statins, fibrates, niacin, ezetimibe, high-dose omega-3 supplements, GLP-1 receptor agonists, SGLT2 inhibitors, or systemic corticosteroids (regular use within the past 3 months) * Presence of rheumatologic diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus) or active malignancy * Neurological disorders (e.g., polyneuropathy, multiple sclerosis, history of stroke) * Pregnancy or lactation * History of lower extremity surgery or major trauma within the past 6 months * Received injection therapy or physical therapy for the lower extremities within the past 6 months * Active infection or dermatological disease affecting the lower extremities * History of significant venous insufficiency or acute deep vein thrombosis (DVT) * Alcohol or substance abuse * Smoking
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Triglyceride-Glucose Index (TyG): | Baseline | The TyG index will be calculated as ln \[fasting triglycerides (mg/dL) × fasting glucose (mg/dL) / 2\]. It serves as a surrogate marker for insulin resistance. Higher values indicate greater metabolic risk. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| TyG-BMI | Baseline | Calculated by multiplying the TyG index by body mass index (BMI). Higher values indicate increased insulin resistance and metabolic risk. |
| Atherogenic Index of Plasma (AIP): | Baseline | Calculated as log (triglycerides / HDL-cholesterol). Higher AIP values reflect greater atherogenic risk. |
| Atherogenic Coefficient (AC): | Baseline | Calculated as (total cholesterol - HDL-cholesterol) / HDL-cholesterol. Higher scores indicate higher atherogenic potential. |
| Castelli Risk Index I (CRI-I): | Baseline | Calculated as total cholesterol / HDL-cholesterol. Higher values indicate increased cardiovascular risk. |
| Castelli Risk Index II (CRI-II): | Baseline | Calculated as LDL-cholesterol / HDL-cholesterol. Higher scores represent greater atherogenic risk. |
Countries
Turkey (Türkiye)
Outcome results
None listed